Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound

• The Danish drugmaker announced that this offer is applicable to cash-pay patients looking to buy introductory doses of Wegovy and Ozempic.
• The company stated that patients can get 0.25 mg and 0.5 mg doses of the two drugs for $199 a month for two months.
• After the first two months, patients can get Wegovy and Ozempic through the company’s direct-to-consumer portal for $349 a month, 30% lower compared to the previous price of $499.

Novo Nordisk AS (NVO) on Monday announced that it will offer its blockbuster obesity and diabetes drugs, Wegovy and Ozempic, for $199 a month to patients in the U.S. as it looks to take on rival Eli Lilly and Co.’s (LLY) Zepbound.

The Danish drugmaker announced that this offer is applicable to cash-pay patients looking to buy introductory doses of Wegovy and Ozempic. The company stated that patients can receive doses of 0.25 mg and 0.5 mg of the two drugs for $199 per month for a period of two months. The offer is available from November 17, 2025, to March 31, 2026.

Novo Nordisk shares were down more than 1% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.

Prices Slashed

Apart from the two-month introductory offer for the two introductory doses of Wegovy and Ozempic, Novo Nordisk has also announced that it will lower the prices of the two drugs for uninsured and self-pay patients.

After the first two months, patients can get Wegovy and Ozempic through the company’s direct-to-consumer portal for $349 a month, 30% lower compared to the previous price of $499.

“Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay,” said Dave Moore, Executive Vice President, US Operations of Novo Nordisk.

Taking On Zepbound

At $349, Novo Nordisk’s new prices for Wegovy and Ozempic match those of Eli Lilly’s Zepbound for the low dose of the obesity shot.

Zepbound is currently available for $349 a month for the 2.5 mg dose for uninsured patients. Prices go up to $1,049 a month for the highest dose of 15 mg, according to the company.

NVO stock is down 44% year-to-date and 53% over the past 12 months.

Also See: Jeff Bezos Returns To An Operating Role As Co-CEO Of AI Startup Project Prometheus: Report

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on